1. Study on psychoeducation enhancing results of adherence in patients with schizophrenia (SPERA-S): study protocol for a randomized controlled trial
- Author
-
Petretto, Dr, Preti, A, Zuddas, C, Veltro, F, Rocchi, Mb, Sisti, D, Martinelli, V, Carta, Mg, Masala, C, Alfa, Rita, Arcidiacono, E, Aguglia, E, Bonanni, E, Borea, M, Consolazione, M, De Giglio, P, DI ROSA, Antonio, Faravelli, C, Fioravanti, G, Fiori Nastro, P, Floris, A, Floris, F, Iannone, C, Iuso, S, La Verde, M, Laffranchini, L, Lecca, Me, Sauro, Cl, Magni, Lr, Margari, F, Marras, M, Marzano, L, Masotti, E, Matta, C, Minutolo, G, Moro, Mf, Mura, G, Nardini, M, Nicchiniello, I, Padalino, F, Papini, Mn, Pastore, A, Petito, A, Pioli, R, Porfiri, Gm, Pullara, A, Sancassiani, F, Seu, Mi, Stallone, V, Vinci, S, and Zappone, L.
- Subjects
Research design ,Health Knowledge, Attitudes, Practice ,Time Factors ,medicine.medical_treatment ,Medicine (miscellaneous) ,Adherence to pharmacotherapy ,Caregiver ,Falloon's method ,Family ,Psychoeducation ,Randomized controlled trial ,Schizophrenia ,law.invention ,Study Protocol ,Clinical Protocols ,Cost of Illness ,Recurrence ,law ,Surveys and Questionnaires ,Pharmacology (medical) ,Chromatography, High Pressure Liquid ,Intention to Treat Analysis ,Treatment Outcome ,Caregivers ,Italy ,Research Design ,Schizophrenic Psychology ,Family Relations ,Drug Monitoring ,Psychosocial ,Antipsychotic Agents ,medicine.medical_specialty ,Blinding ,Medication Adherence ,Pharmacotherapy ,Patient Education as Topic ,schizophrenia ,Psychological adjustment ,caregivers ,medicine ,Humans ,Psychiatry ,Psychiatric Status Rating Scales ,Intention-to-treat analysis ,business.industry ,Falloon’s method ,Supportive psychotherapy ,Physical therapy ,Feasibility Studies ,business - Abstract
Poor adherence to pharmacotherapy negatively affects the course and the outcome of schizophreniaspectrum psychoses, enhancing the risk of relapse. Falloon and coworkers developed a Psychoeducation Program aimed at improving communication and problem-solving abilities in patients and their families. This study set out to evaluate changes in adherence to pharmacotherapy in patients diagnosed with schizophrenia-spectrum psychoses, by comparing one group exposed to the Falloon Psychoeducation Program (FPP) with another group exposed to family supportive therapy with generic information on the disorders. 340 patients diagnosed with schizophrenia and related disorders according to standardized criteria from 10 participating units distributed throughout the Italian National Health System (NHS), will be enrolled with 1:1 allocation by the method of blocks of randomized permutations. Patients will be reassessed at 6, 12 and 18 months after start of treatment (duration: 6 months). The primary objective is to evaluate changes in adherence to pharmacotherapy after psychoeducation. Adherence will be assessed at three-month intervals by measuring blood levels of the primary prescribed drug using high pressure liquid chromatography, and via the Medication Adherence Questionnaire and a modified version of the Adherence Interview. Secondary objectives are changes in the frequency of relapse and readmission, as the main indicator of the course of the disorder. Enrolled patients will be allocated to the FPP (yes/no) randomly, 1:1, in a procedure controlled by the coordinating unit; codes will be masked until the conclusion of the protocol (or the occurrence of a severe negative event). The raters will be blind to treatment allocation and will be tested for blinding after treatment completion. Intention-to-treat will be applied in considering the primary and secondary outcomes. Multiple imputations will be applied to integrate the missing data. The study started recruitment in February 2013; the total duration of the study is 27 months. If the psychoeducation program proves effective in improving adherence to pharmacotherapy and in reducing relapse and readmissions, its application could be proposed as a standard adjunctive psychosocial treatment within the Italian NHS. Protocol Registration System of ClinicalTrials.gov NCT01433094 ; registered on 20 August 2011; first patient was randomized on 12 February 2013.
- Full Text
- View/download PDF